Zevra Therapeutics表示，预计将在2026年下半年继续与美国食品药品监督管理局（FDA）保持互动。此举旨在探寻多种可能路径，以求加速其临床开发进程。这家制药公司正积极寻求监管层面的支持，从而推动相关治疗方案的快速落地与拓展。
Zevra Therapeutics表示，预计将在2026年下半年继续与美国食品药品监督管理局（FDA）保持互动。此举旨在探寻多种可能路径，以求加速其临床开发进程。这家制药公司正积极寻求监管层面的支持，从而推动相关治疗方案的快速落地与拓展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.